Developing brain-cell models and small-molecule therapies for neurodegeneration
Neurodegenerative diseases progressively impair memory, movement and independence, while treatment options remain limited. Drug development is also hindered by laboratory models that do not fully reproduce human disease, making it difficult to identify therapies that will work in patients.
FloBiotech develops human brain-cell models and small-molecule therapies for neurodegenerative diseases. Its work aims to improve drug testing and support the brain’s protective pathways, with an initial focus on Alzheimer’s disease and related tau disorders.
What stands out about FloBiotech
FloBiotech licensed UCLA Health’s preclinical DDL-357 compound in June 2026 to develop neurodegenerative disease treatments.
Licensed DDL-357 improved memory tests and reduced a brain tau marker in a six-week Alzheimer’s mouse study with 13 animals per group.
FloBiotech announced CHF 400,000 in founders’ financing in February 2025 and later closed a CHF 450,000 Friends & Family round.
FloBiotech established a scientific collaboration with UCLA Health alongside its June 2026 licence for neurodegenerative drug development.
Co-founder Loïc Galera was Myovant Sciences’ global supply-chain VP, building operations for three launches in North America and Europe.
Co-founder Baltazar Gomez-Mancilla led neuroscience translational medicine at Novartis and later became STALICLA’s chief medical officer.
Co-founder Florence Clavaguera conducted foundational tau-pathology research at University Hospital Basel and won a 2013 Alzheimer’s research prize.
Co-founder Baltazar Gomez-Mancilla is a physician-scientist and clinical neurologist with more than 30 years of CNS drug-development experience.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.